TREATMENT UPTAKE AND REAL WORLD EFFECTIVENESS OF SOFOSBUVIR/LEDIPASVIR AND PARITAPREVIR/RITONAVIR/OMBITASVIR/DASABUVIR AMONG HCV-INFECTED PERSONS WITH CHRONIC KIDNEY DISEASE

被引：0
|
作者：
Alkadi, Mohamad
Ren, Yanjie
Puenpatom, Amy
Kumar, Ritesh
Arduino, Jean Marie
Abou-Samra, Abdul-Badi
Butt, Adeel
机构：
来源：
GASTROENTEROLOGY | 2017年 / 152卷 / 05期
关键词：
D O I：
10.1016/S0016-5085(17)33707-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1536
引用
收藏
页码：S1100 / S1101
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease
    El-Sayed, Mohammad
    Elserafy, Magdy
    El Raziky, Maissa
    Elakel, Wafaa
    Saad, Yasmin
    Fayad, Tarek
    Korany, Mohamed
    Mehrez, Mai
    Salama, Rabab
    Mahrous, Maged
    Zaki, Ayman
    Hassany, Mohamed
    Ammar, Islam
    Elsaeed, Kadry
    Elshazly, Yehia
    Doss, Wahid
    ARAB JOURNAL OF GASTROENTEROLOGY, 2023, 24 (01) : 29 - 33
  • [32] Comparative effectiveness of ledipasvir/sofosbuvir±ribavirin vs. ombitasvir/paritaprevir/ritonavir plus dasabuvir±ribavirin in 6961 genotype 1 patients treated in routine medical practice
    Backus, L. I.
    Belperio, P. S.
    Shahoumian, T. A.
    Loomis, T. P.
    Mole, L. A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (04) : 400 - 410
  • [33] The efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir and ledipasvir/sofosbuvir is similar in patients who failed interferon-based treatment with first generation protease inhibitors
    Janczewska, E.
    Flisiak, R.
    Zarebska-Michaluk, D.
    Arkadiusz, P.
    Staniaszek, A.
    Gietka, A.
    Mazur, W.
    Tudrujek, M.
    Tomasiewicz, K.
    Belica-Wdowik, T.
    Baka-Cwierz, B.
    Dybowska, D.
    Halota, W.
    Lorenc, B.
    Sitko, M.
    Garlicki, A.
    Berak, H.
    Andrzej, H.
    Orlowska, I.
    Krzysztof, S.
    Socha, L.
    Wawrzynowicz-Syczewska, M.
    Jaroszewicz, J.
    Zbigniew, D.
    Czauz-Andrzejuk, A.
    Citko, J.
    Krygier, R.
    Piekarska, A.
    Laurans, L.
    Dobracka, B.
    Bialkowska-Warzecha, J.
    Olga, T.
    Pawlowska, M.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S277 - S277
  • [34] High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease
    Sanai, Faisal M.
    Alghamdi, Abdullah S.
    Afghani, Ahmad A.
    Alswat, Khalid
    AlZanbagi, Adnan
    Alghamdi, Mosfer N.
    AlMousa, Abdallah
    Aseeri, Mohammed
    Assiri, Abdullah M.
    Babatin, Mohamed A.
    LIVER INTERNATIONAL, 2018, 38 (08) : 1395 - 1401
  • [35] CORRELATES OF TWELVE WEEK TREATMENT ADHERENCE AMONG PATIENTS WITH HEPATITIS C NEWLY INITIATING DIRECT ACTING ANTIVIRAL THERAPIES INCLUDING SOFOSBUVIR CONTAINING, LEDIPASVIR/SOFOSBUVIR AND OMBITASVIR/PARITAPREVIR/RITONAVIR-DASABUVIR REGIMENS
    Shcherbakova, N.
    Tereso, G.
    Colby, A.
    D'Angelo, L.
    VALUE IN HEALTH, 2017, 20 (05) : A185 - A185
  • [36] PREDICTORS OF HEPATIC DECOMPENSATION DURING OMBITASVIR/PARITAPREVIR/RITONAVIR ± DASABUVIR ± RIBAVIRIN TREATMENT OF GENOTYPE 1 AND 4 HCV INFECTED PATIENTS (REAL LIFE AMBER STUDY)
    Flisiak, R.
    Jaroszewicz, J.
    Janczewska, E.
    Wawrzynowicz-Syczewska, M.
    Grabinska, A.
    Bolewska, B.
    Pisula, A.
    Karpinska, E.
    Mozer-Lisewska, I.
    Madej, G.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S815 - S815
  • [37] Treatment of adolescents genotype 4 chronic HCV infected patients with Ledipasvir/Sofosbuvir combination: A real world experience
    Khayat, H. E.
    Kamal, I.
    El-Sayed, M. H.
    Ayoub, H.
    Shabrawy, M. E.
    Rizk, A.
    Yehia, R.
    Maher, M.
    Fouad, Y.
    Attia, D.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S327 - S327
  • [38] PREDICTORS OF FAST RESPONSE TO OMBITASVIR/PARITAPREVIR/RITONAVIR ± DASABUVIR ± RIBAVIRIN IN REAL LIFE AMBER STUDY IN GENOTYPE 1 AND 4 HCV INFECTED PATIENTS AS A RATIONALE FOR SHORTENING OF TREATMENT
    Flisiak, R.
    Jaroszewicz, J.
    Janczewska, E.
    Wawrzynowicz-Syczewska, M.
    Nazzal, K.
    Bolewska, B.
    Bialkowska, J.
    Zarebska-Michaluk, D.
    Berak, H.
    Fleischer-Stepniewska, K.
    Tudrujek, M.
    Karwowska, K.
    Rostkowska, K.
    Piekarska, A.
    Tronina, O.
    Grabinska, A.
    Garlicki, A.
    Lucejko, M.
    Pisula, A.
    Karpinska, E.
    Wiercinska-Drapalo, A.
    Mozer-Lisewska, I.
    Jablkowski, M.
    Kryczka, W.
    Horban, A.
    Knysz, B.
    Tomasiewicz, K.
    Halota, W.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S815 - S815
  • [39] Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences
    Ormeci, Necati
    Sezgin, Orhan
    Karaali, Ridvan
    Aygen, Bilgehan
    Turan, Dilara
    Yaras, Serkan
    Erdem, Ilknur
    Yildiz, Orhan
    Karakaya, Fatih
    Ates, Kenan
    Asillee, Ozgun O.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (04) : 534 - 539
  • [40] COST-EFFECTIVENESS ANALYSIS OF DACLATASVIR WITH ASUNAPREVIR VS PARITAPREVIR/RITONAVIR/OMBITASVIR WITH DASABUVIR IN TREATMENT OF CHRONIC HEPATITIS C IN THE RUSSIAN FEDERATION
    Yagudina, R.
    Kulikov, A.
    Babiy, V. V.
    VALUE IN HEALTH, 2016, 19 (07) : A415 - A416
12345